It is learned that Zhejiang Youyi Medical Devices Co., Ltd. (hereinafter referred to as “Yiyi Medicalâ€) has obtained strategic investment of tens of millions of yuan from Yida Capital's fund, Jiangsu Yida Achievements Innovation and Venture Capital Fund (Limited Partnership). Founded in 2010, Youyi Medical is a state-level high-tech enterprise engaged in the development of visual medical device products. The arterial network learned that the company's products are closely arranged around the perioperative visual medical products . The company's existing products are developed around airway management, with the aim of solving the series of pain points of clinicians in airway management. Arterial Network learned that in 2016, Youyi Medical obtained Tianjin Ada A round of financing. After two years of development, in the case of sufficient self-hematopoietic capacity, it has received tens of millions of dollars in financing from Yida Capital. In the case of sufficient hematopoietic capacity, why should Youyi Medical carry out this round of financing? After financing, what is the next step for Youyi Medical? In the eyes of investors, where is the core competitiveness of Youyi Medical? To this end, the arterial network interviewed Xue Yi, a core team member of Youyi Medical and a business partner of Yida Capital. In the case of self-hematopoietic, why should we complete this round of financing? The members of the core team of Youyi Medical told the Arterial Network that in the field of medical devices, the company's own hematopoietic function and innovative ability are very important. As a company itself, we must make solid business models and financial models, especially the two ports of research and development capabilities and marketing promotion. The enterprise itself must have “real talents†and “true valueâ€. According to the arterial network, the products that have been marketed include the visual laryngoscope, the visual rigid laryngoscope, the visual soft laryngoscope, and the visual laryngeal mask. Among them, the video laryngoscope has covered more than 6,000 large and medium-sized hospitals in China, with a market share of more than 70%, and the coverage rate of the top three hospitals is over 75%. The member said that although Euplus Medical currently has a healthy cash flow, with the help of capital, it can accelerate the development of Youyi Medical in the industrial layout of international vision. First, Youyi Medical will increase the research and development of visual products, and adhere to the research and development concept of “from clinical to clinical†to achieve more transformational medical products and launch more products to meet clinical needs. , in the fields of anesthesia, emergency, severe, respiratory and other fields have made great progress; Second, Youyi Medical will invest in the layout of high-end projects in the upstream and downstream, create an intelligent medical device industry chain platform, and strive to realize the visualization, intelligence, informationization and dataization of the whole process of the industrial chain; Third, Youyi Medical has consistently adhered to the marketing strategy of promoting the market, and with the help of capital, it will invest more in the market, in order to make the company's high-quality products play their due value. According to the arterial network, Youyi Medical has been actively deploying overseas markets since its inception. It has established a foreign trade center in Shanghai and established offices in the United States. The products are exported to the United States, Germany, France, Italy, Belgium, South Korea, etc. 35 countries and regions. It is worth mentioning that Youyi Medical has always paid attention to the protection of its own intellectual property rights. At present, Youyi Medical has more than 100 national patents and dozens of international invention patents. Yida Capital: Paying attention to the professional team of “Yiyi Medical†and the spirit of “concentration†The investment business of Yida Capital Management Team began in 1992. As of the end of November 2018, Yida Capital Management Team has established a total of 85 differently positioned equity investment funds with a management capital of 93.7 billion yuan. The accumulated investment supported 720 start-ups, boosting 158 of them to land in domestic and overseas capital markets. Arterial Network has learned that in recent years, Yida Capital has invested in more than 40 large-scale health enterprises with an investment of more than 1.4 billion yuan, focusing on various segments such as bio-pharmaceuticals, medical services, innovative devices, and precision medical treatment . "We are honored to be associated with Youyi Medical and become a long-term partner." Xue Wei said that the core reasons for Yida Capital to look at the company are as follows: First, Youyi Medical has a stable core backbone team of more than 60 people. Its core team gathers together through the “equity incentive systemâ€. Team members and clinical experts have reached in-depth cooperation and done better in translational medicine. Secondly, Youyi Medical has invested heavily in the research and development of visualized medical devices in the perioperative period, and has focused on the perioperative period of visual medical device field for nearly ten years; Third, Yida Capital recognizes the direction of choice for Youyi Medical. After investing in Youyi Medical, in addition to providing financial support, Yida Capital will also help Youyi Medical in the field of corporate regulation and securities. Yida Capital and Youyi Medical will jointly develop in the field of medical device visualization. The cooperation between Youyi Medical and Yida Capital will give them an edge and strive to build Youyi Medical into a world-class enterprise in the field of visual medical devices. Antineoplastic,Antineoplastic Agents,Natural Antineoplastic,Methotrexate Antineoplastic NOUVASANT GROUP LTD. , https://www.nouvasant.com